ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency...
ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency...
Type 1 allergic reactions can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, foods, medication, exercise, or other unknown causes. Studies show that up to 18% of children with food allergies have had a reaction from accidentally eating food allergens while at school.1 In addition, 25% of severe and potentially life-threatening reactions (anaphylaxis) reported at schools happened in children with no previous diagnosis of food allergy.1 ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency Situations At No Cost To The School
ARS制药公司宣布将于2025年1月推出NeffyinSchools计划；该计划将为美国符合条件的公立和私立K-12学校提供两箱Neffy 2mg，以便在紧急情况下免费供学校使用
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy (epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis
符合条件的美国公立和私立K-12学校将有资格免费获得两箱（四剂单次使用剂量）neffy（肾上腺素鼻喷雾剂）2mg，以用于过敏反应的紧急治疗，包括过敏性休克
Interested schools are encouraged to review applicable state laws and regulations to ensure neffy for undesignated use meets all requirements
鼓励有意向的学校查看适用的州法律和法规，以确保未指定用途的neffy符合所有要求
SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that it will be launching the neffyinSchools Program in January 2025. The program will provide eligible public and private K-12 schools in the U.S. the opportunity to receive two cartons (four single use doses) of neffy (epinephrine nasal spray) 2mg for use in emergency situations at no cost to the school. neffy 2mg was recently approved for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.) Participating schools will be eligible to receive replacement doses when the product is used or expires.
圣地亚哥，2024年12月4日（全球新闻网）—— ARS制药公司（纳斯达克：SPRY），一家致力于赋能高风险患者及其护理人员更好地保护自己免受可能导致过敏性休克的过敏反应的生物制药公司，今天宣布将于2025年1月推出neffyinSchools计划。该计划将为美国符合条件的公立和私立K-12学校提供机会，获得两箱（四剂单次使用剂量）的neffy（肾上腺素鼻喷雾剂）2mg，以便在紧急情况下免费供学校使用。neffy 2mg最近获得批准，用于治疗体重≥30 kg（66磅）成人和儿童的Ⅰ型过敏反应，包括过敏性休克。参与学校在产品使用或过期时将有资格获得替代剂量。
Type 1 allergic reactions can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, foods, medication, exercise, or other unknown causes. Studies show that up to 18% of children with food allergies have had a reaction from accidentally eating food allergens while at school.1 In addition, 25% of severe and potentially life-threatening reactions (anaphylaxis) reported at schools happened in children with no previous diagnosis of food allergy.1
Ⅰ型过敏反应可能危及生命，可能在几分钟内发生，并可能由叮咬和咬伤的昆虫、食物、药物、运动或其他未知原因引起。研究显示，最多有18%的食物过敏儿童在学校意外食用食物过敏原时发生了反应。此外，在学校报告的重度和潜在危及生命的反应（过敏性休克）中，有25%发生在没有食物过敏既往诊断的儿童身上。
